Newly formed Mage Biologics Inc. is set to receive investment of $28 million from TVM Capital Life Science and Tillotts Pharma AG. Mage plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (MAb) for an initial indication of ulcerative colitis.
Researchers from the Chinese University of Hong Kong have identified the Carnobacterium maltaromaticum bacterium as a potential oral probiotic prophylactic to increase vitamin D production and reinvigorate gut microbiota to prevent colorectal cancer (CRC) in women.
Researchers based at Northwestern University Feinberg School of Medicine have discovered that a lack of contact between mitochondria and lysosomes in the cells of patients with a genetic form of Parkinson’s disease likely contributed to their symptoms.
Work at Shanghai Haihe Biopharma Co. Ltd. has led to the development of pyrimidine-2(1H)-one-fused bicyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors and thus reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co. KG has prepared and tested heteroaromatic compounds described as GTPase KRAS G12C mutant inhibitors and reported to be useful for the treatment of cancer.
RSS
